http://chineseinput.net/에서 pinyin(병음)방식으로 중국어를 변환할 수 있습니다.
변환된 중국어를 복사하여 사용하시면 됩니다.
In situ Sodium Alginate-Hyaluronic Acid Hydrogel Coating Method for Clinical Applications
Ying Liu,정동준,Li Jie Duan,김민지,김지흥 한국고분자학회 2014 Macromolecular Research Vol.22 No.3
A novel synthetic method is reported to prepare HAAL hydrogels derived from hyaluronic acid (HA) andsodium alginate (AL) with different compositions (ranging from 1:1 to 1:5) through ionic and covalent crosslinkingis reported in this study. The synthesized hydrogels were characterized by FTIR spectroscopy. Surface morphologyand equilibrium swelling behavior of the hydrogels were also examined. In an MTT assay, the hydrogel extractswere found to be non-cytotoxic to L929 mouse fibroblasts. The blood compatibility of the synthesized hydrogelswas assayed with a platelet adhesion test, and was comparable with that of medical-grade polyurethane (PU, Pellethane®). HAAL hydrogels with recombinant human epidermal growth factor (rh-EGF) exhibited enhanced cell proliferationand adhesion (human L929 fibroblast). These characteristics demonstrate that HAAL hydrogels treatedusing this in situ coating method have potential for usage in various clinical applications.
Use of grape seed as reductant for leaching of cobalt from spent lithium-ion batteries
Ying-Jie Zhang,Qi Meng,Peng Dong,Jianguo Duan,Yan Lin 한국공업화학회 2018 Journal of Industrial and Engineering Chemistry Vol.66 No.-
The grape seed was novelly used as reductant for leaching of spent LiCoO2 material, which is idea of “waste + waste → resources”. About 92% Co and 99% Li could be leached under the optimized conditions of grape seed 0.6 g/g, malic acid 1.5 mol/L, 180 min, 80 °C, and slurry density 20 g/L. The catechin, EC and EGCG contained in grape seed could be employed as efficient reductants during leaching. The leaching process is controlled by combination of surface chemical reaction and diffusion with apparent activation energy of 11.96 kJ/mol, which is related to the form of Co(OH)3.
Qi Meng,Jianguo Duan,Ying-Jie Zhang,Peng Dong 한국공업화학회 2019 Journal of Industrial and Engineering Chemistry Vol.80 No.-
In this study, a novel efficient and environmentally friendly recycling process is developed to recoverspent LiMn2O4 powder as raw materials for high-performance LiMnPO4/C nanocomposites. The processcomprises a mechanochemical liquid-phase activation of the precursor mixture followed by a single-stepsolid-state heat treatment. The results indicate that the recovered LiMnPO4/C nano-composite has apromising electrochemical performance with discharge capacities of 148.5, 136.1, and 116.5 mA h g 1 at0.05, 0.2, and 1C rate, respectively, in the voltage range of 2.5–4.5 V. A perfect cyclic performance is alsodisplayed with a capacity retention of 98% after 100 cycles at 1C rate.
Wang Lu,Dai Ying-Jie,Cui Yu,Zhang Hong,Jiang Chang-Hao,Duan Ying-Jie,Zhao Yong,Feng Ye-Fang,Geng Shi-Mei,Zhang Zai-Hui,Lu Jiang,Zhang Ping,Zhao Li-Wei,Zhao Hang,Ma Yu-Tong,Song Cheng-Guang,Zhang Yi,Ch 대한뇌졸중학회 2023 Journal of stroke Vol.25 No.3
Background and Purpose Intravenous tenecteplase (TNK) efficacy has not been well demonstrated in acute ischemic stroke (AIS) beyond 4.5 hours after onset. This study aimed to determine the effect of intravenous TNK for AIS within 4.5 to 24 hours of onset. Methods In this pilot trial, eligible AIS patients with diffusion-weighted imaging (DWI)-fluid attenuated inversion recovery (FLAIR) mismatch were randomly allocated to intravenous TNK (0.25 mg/kg) or standard care within 4.5–24 hours of onset. The primary endpoint was excellent functional outcome at 90 days (modified Rankin Scale [mRS] score of 0–1). The primary safety endpoint was symptomatic intracranial hemorrhage (sICH). Results Of the randomly assigned 80 patients, the primary endpoint occurred in 52.5% (21/40) of TNK group and 50.0% (20/40) of control group, with no significant difference (unadjusted odds ratio, 1.11; 95% confidence interval 0.46–2.66; <i>P</i>=0.82). More early neurological improvement occurred in TNK group than in control group (11 vs. 3, <i>P</i>=0.03), but no significant differences were found in other secondary endpoints, such as mRS 0–2 at 90 days, shift analysis of mRS at 90 days, and change in National Institutes of Health Stroke Scale score at 24 hours and 7 days. There were no cases of sICH in this trial; however, asymptomatic intracranial hemorrhage occurred in 3 of the 40 patients (7.5%) in the TNK group. Conclusion This phase 2, randomized, multicenter study suggests that intravenous TNK within 4.5–24 hours of onset may be safe and feasible in AIS patients with a DWI-FLAIR mismatch.